Market: NMS |
Currency:
Address:
📈 ORR Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
-
-
Net Income Growth Range (1Y):
-
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for ORR
No earnings history available for this symbol.
📰 Related News & Research
-
Bright Mountain Media, Inc. Files Amendment to Correct Reporting Item on Form 8-K/A (April 6, 2026)
April 7, 2026
Bright Mountain Media, Inc. Files Amendment to 8-K: Signific...
-
Titan Acquisition Corp. 2025 Annual Report Amendment: Financial Statements, Audit Correction, and SPAC Operations Overview
April 7, 2026
Titan Acquisition Corp. Files Amended 10-K: What Investors N...
-
Torrid Holdings Inc. Files Form 8-K with SEC Detailing Company Information and NYSE Listing
April 4, 2026
Torrid Holdings Inc. Announces Appointment of New Chief Comm...
-
Spruce Power Holding Corp 2025 Annual Report Amendment: Financial Corrections, Auditor Changes, and Key Financial Data
April 4, 2026
Spruce Power Holding Corporation Files Amended Annual Report...
-
Monopar Therapeutics Inc. 2025 Annual Report Amendment: Financial Highlights, Corrections, and Key SEC Filings
April 2, 2026
Monopar Therapeutics Inc. 10-K/A Detailed Report Summary ...
-
Immix Biopharma, Inc. 2025 Annual Report Amendment: Financial Statements, Auditor Correction, and Company Overview
March 28, 2026
Immix Biopharma, Inc. Files Amendment No. 1 to Annual Report...
-
Mills Music Trust Announces Q4 2025 Royalty Distribution and Overpayment Correction in 2026 Quarterly Report
March 26, 2026
Mills Music Trust Q1 2026 Investor Update Mills Music ...
-
FVCBankcorp, Inc. 2025 Annual Report Amendment: Corrected Certifications, Risk Factors, and Financial Overview
March 26, 2026
FVCBankcorp, Inc. Files Amendment No. 1 to 2025 Annual Repor...
-
Ensysce Biosciences Files Certificate of Correction for Series B Preferred Stock with Delaware Secretary of State
March 23, 2026
Ensysce Biosciences, Inc. Files Certificate of Correction fo...
-
60 Degrees Pharmaceuticals, Inc. Corrects Prospectus Supplement Disclosure in SEC Form 8-K Filing (March 20, 2026)
March 21, 2026
60 Degrees Pharmaceuticals, Inc. Files Form 8-K: Correction ...
🔍 View more Reports